Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: Focus on levodopa/carbidopa/entacapone

Expert Review of Neurotherapeutics

Volumn 12, Issue 2, 2012, Pages 119-131

  Reichmann, Heinz ^a   Emre, Murat ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

entacapone; levodopa levodopa carbidopa entacapone; motor fluctuations; Parkinson's disease; wearing off

Indexed keywords

BENSERAZIDE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; IMPAX; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PRAMIPEXOLE; ROPINIROLE; TOLCAPONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BASAL GANGLION; CLOSED ANGLE GLAUCOMA; COHORT ANALYSIS; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; ELECTROCARDIOGRAM; HALLUCINATION; HAZARD RATIO; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; PHEOCHROMOCYTOMA; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL ANALOG SCALE;

ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOLS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; LEVODOPA; NITRILES; PARKINSON DISEASE;

EID: 84856599855     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.203     Document Type: Review

References (91)

1. Karlsen KH, Tandberg E, Arsland D, Larsen JP. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J. Neurol. Neurosurg. Psychiatry 69(5), 584-589 (2000).
2. De Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11 Suppl. 5), S21-S23 (2000). (Pubitemid 30390601)
3. Rajput AH. Frequency and cause of Parkinson's disease. Can J. Neurol. Sci. 19(1 Suppl.), 103-107 (1992).
4. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 363(9423), 1783-1793 (2004). (Pubitemid 38698383)
5. Golbe LI. Young-onset Parkinson's disease: a clinical review. Neurology 41(2 Pt 1), 168-173 (1991).
6. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N. Engl. J. Med. 339(16), 1130-1143 (1998). (Pubitemid 28465762)
7. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 23(10 Suppl.), S8-S19 (2000).
8. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann. Neurol. 36(5), 759-764 (1994).
9. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114(Pt 5), 2283-2301 (1991).
10. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72(21 Suppl. 4), S1-S136 (2009).
11. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov. Disord. 15(3), 503-510 (2000). (Pubitemid 30333223)
12. Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J. Neurol. Sci. 175(1), 3-12 (2000). (Pubitemid 30227477)
13. Gerschlager W, Bencsits G, Pirker W, et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov. Disord. 17(3), 518-523 (2002). (Pubitemid 36040965)
14. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann. Neurol. 59(3), 559-562 (2006). (Pubitemid 43358078)
15. Brooks DJ. Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr. Dis. Treat. 4(1), 39-47 (2008). (Pubitemid 351460978)
16. Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. Eur. J. Neurol. 16(9), 982-989 (2009).
17. Poewe W, Antonini A, Zijlmans JCM, Burkhard PR, Vingerhoetz F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin. Interv. Aging 5, 229-238 (2010).
18. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16(3), 448-458 (2001). (Pubitemid 36041148)
19. Hattori N, Fujimoto K, Kondo T, Murata M, Stacy M. Patient perspectives towards levodopa therapy in Japan and the United States -results of two patient surveys. Mov. Disord. 25(Suppl. 3), S569-S717 (2010).
20. Stocchi F. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Expert Opin. Pharmacother. 7(10), 1399-1407 (2006).
21. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Disord. 19(9), 997 (2004).
22. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276(7), 374-379 (1967).
23. Birkmayer W, Hornykiewics O. The effect of l-3,4-dihydroxyphenlyalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat. Disord. 4(2), 59-60 (1998). (Pubitemid 28525350)
24. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat. Disord. 8(2), 95-100 (2001). (Pubitemid 32728022)
25. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55(Suppl. 1), 23-30 (1998). (Pubitemid 28051035)
26. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 61(7), 1044-1053 (2004). (Pubitemid 38915945)
27. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomised controlled trial. JAMA 284(15), 1931-1938 (2000).
28. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov. Disord. 22(16), 2409-2417 (2007). (Pubitemid 351155989)
29. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 307, 469-472 (1993).
30. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov. Disord. 21(3), 343-353 (2006).
31. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342(20), 1484-1491 (2000). (Pubitemid 30318272)
32. Parkinson Study Group. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch. Neurol. 66(5), 563-570 (2009).
33. Hauser RA, Holford NH. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov. Disord. 17(5), 961-968 (2002). (Pubitemid 36041001)
34. Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Mov. Disord. 15(3), 485-489 (2000). (Pubitemid 30333220)
35. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 55(11 Suppl. 4), S13-S20 (2000).
36. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov. Disord. 20(2), 224-230 (2005). (Pubitemid 40361128)
37. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56(11 Suppl. 5), S1-S88 (2001). (Pubitemid 32532291)
38. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351(24), 2498-2508 (2004).
39. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71(7), 474-480 (2008).
40. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin. Pharmacokinet. 45(2), 109-136 (2006). (Pubitemid 43290827)
41. Pahwa R, Lyons KE. Levodopa-related wearing-off in Parkinson's disease: identification and management. Curr. Med. Res. Opin. 25(4), 841-849 (2009).
42. Oertel WH, Berardelli A, Bloem BR, et al. Late (complicated) Parkinson's disease. In: European Handbook of Neurological Management. Gilhus NE, Barnes MR, Brainin M (Eds). Wiley-Blackwell, Hoboken, NJ, USA, 584 (2010).
43. Kuoppamäki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four-or five-times daily. Eur. J. Clin. Pharmacol. 65(5), 443-455 (2009).
44. Nutt JG, Carter JH, Lea ES, Woodward WR. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov. Disord. 12(3), 285-292 (1997). (Pubitemid 27216124)
45. Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr. Clin. Pharmacol. 2(3), 234-243 (2007). (Pubitemid 47520962)
46. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44(5), 913-919 (1994). (Pubitemid 24158809)
47. Myllylä VV, Sotaniemi KA, Illi A, Suominen K, Keranen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur. J. Clin. Pharmacol. 45, 419-423 (1993). (Pubitemid 23361940)
48. Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin. Neuropharmacol. 16(2), 145-156 (1993). (Pubitemid 23090692)
49. Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibitors of catechol o-methyltransferase. Gen. Pharmacol. 25(5), 813-824 (1994). (Pubitemid 24295641)
50. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A. Effect of entacapone, a peripherally acting catechol-o-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 57, 186-189 (1994). (Pubitemid 24050458)
51. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin. Neuropharmacol. 19(4), 283-296 (1996). (Pubitemid 26250111)
52. Sawle GV, Burn DJ, Morrish PK, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 44(7), 1292-1297 (1994).
53. Kuoppamäki M, Sauramo A, Korpela K, et al. Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared with controlled-release levodopa/carbidopa. Int. J. Clin. Pharmacol. Ther. 48(11), 756-760 (2010 ).
54. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. NOMECOMT Study Group. Neurology 51(5), 1309-1314 (1998). (Pubitemid 28520549)
55. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol. Scand. 105(4), 245-255 (2002). (Pubitemid 34407226)
56. Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J. Neurol. Neurosurg. Psychiatry 74(8), 1071-1079 (2003).
57. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. Neurol. 42(5), 747-755 (1997).
58. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev. (4), CD004554 (2004).
59. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur. J. Neurol. 10(2), 137-146 (2003). (Pubitemid 36308207)
60. Onofrj M, Thomas A, Vingerhoets F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J. Neural. Transm. 111(8), 1053-1063 (2004). (Pubitemid 39037126)
61. Nissinen H, Kuoppamaki M, Leinonen M, Schapira AH. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis. Eur. J. Neurol. 16(12), 1305-1311 (2009).
62. Eggert K, Skogar O, Amar K, et al. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility -an open-label, 6-week study. J. Neural. Transm. 117(3), 333-342 (2010).
63. Koller W, Guarnieri M, Hubble J, Rabinowicz Al, Silver D. An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J. Neural. Transm. 112(2), 221-230 (2005). (Pubitemid 40179116)
64. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov. Disord. 24(4), 541-550 (2009).
65. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann. Neurol. 68(1), 18-27 (2010).
66. Brooks DJ, Leinonen M, Kuoppamaki M, Nissinen H. Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. J. Neural. Transm. 115(6), 843-849 (2008).
67. Deuschl G, Vaitkus A, Fox GC, Roscher T, Schremmer D, Gordin A. Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. Mov. Disord. 22(11), 1550-1555 (2007). (Pubitemid 47477914)
68. Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology 62(1 Suppl. 1), S39-S46 (2004). (Pubitemid 38082851)
69. Myllylä V, Haapaniemi T, Kaakkola S, et al. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study). Acta Neurol. Scand. 114(3), 181-186 (2006). (Pubitemid 44185911)
70. Linazasoro G, Kulisevsky J, Hernandez B. Should levodopa dose be reduced when switched to Stalevo? Eur. J. Neurol. 15(3), 257-261 (2008). (Pubitemid 351257922)
71. Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov. Disord. 24(6), 826-832 (2009).
72. Ingman K, Naukkarinen T, Vahteristo M, Korpela I, Kuoppamäki M, Ellmén J. The effect of different dosing regimens of levodopa/carbidopa/ entacapone on plasma levodopa concentrations. Eur. J. Clin. Pharmacol. doi:10.1007/s00228-011-1121-5 (2011) (Epub ahead of print).
73. Sethi KD, Hauser RA, Isaacson SH, Mcclain T. Levodopa/carbidopa/ entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series. Cases J. 2, 7134 (2009).
74. Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov. Disord. 18(10), 1139-1145 (2003). (Pubitemid 37336937)
75. Dengler I, Leukel N, Meuser T, Jost WH. [Prospective study of the direct and indirect costs of idiopathic Parkinson's disease]. Der. Nervenarzt. 77(10), 1204-1209 (2006). (Pubitemid 44627679)
76. Keranen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat. Disord. 9(3), 163-168 (2003). (Pubitemid 36173566)
77. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 19(10), 1013-1038 (2001). (Pubitemid 33701931)
78. Findley LJ, Lees A, Apajasalo M, Pitkanen A, Turunen H. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared with standard care in UK Parkinson's disease patients with wearing-off. Curr. Med. Res. Opin. 21(7), 1005-1014 (2005). (Pubitemid 41032689)
79. Palmer CS, Nuijten MJ, Schmier JK, Subedi P, Snyder EH. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. Pharmacoeconomics 20(9), 617-628 (2002).
80. Delea TE, Thomas SK, Hagiwara M. The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis. CNS Drugs 25(1), 53-66 (2010).
81. Hauser RA, Ellenbogen AL, Metman LV, et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Mov. Disord. 26(12), 2246-2252 (2011).
82. Kiss LE, Ferreira HS, Torrao L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-o-methyltransferase. J. Med. Chem. 53(8), 3396-3411 (2010).
83. Kaakkola S. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. Int. Rev. Neurobiol. 95, 207-225 (2010).
84. Morelli M, Carta AR, Jenner P. Adenosine A2A receptors and Parkinson's disease. Handb. Exp. Pharmacol. (193), 589-615 (2009).
85. Sommer DB, Stacy MA. What's in the pipeline for the treatment of Parkinson's disease? Expert Rev. Neurother. 8(12), 1829-1839 (2008).
86. Quik M, Bordia T, Huang L, Perez X. Targeting nicotinic receptors for parkinson's disease therapy. CNS Neurol. Disord. Drug Targets. 10(6), 651-658 (2011).
87. Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH. Neurotrophic factor therapy for Parkinson's disease. Prog. Brain Res. 184, 237-264 (2010).
88. Witt J, Marks WJ Jr. An update on gene therapy in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 11(4), 362-370 (2011).
89. Hilker R, Brotchie JM, Chapman J. Pros and cons of a prion-like pathogenesis in Parkinson's disease. BMC Neurology 11, 74 (2011).
90. Olanow CW, Mcnaught K. Parkinson's disease, proteins, and prions: milestones. Mov. Disord. 26(6), 1056-1071 (2011).
91. Orion Pharma. Stalevo Summary Product Characteristics. www.medicines.org.uk/emc/medicine/21633/SPC/Stalevo+150+37.5+200mg (Accessed August 2011)